CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML

FLT3‐ITD tyrosine kinase inhibitors (TKI) show limited clinical activity in acute myeloid leukemia (AML) due to emerging resistance. TKI resistance is mediated by secondary FLT3‐ITD mutations only in a minority of cases. We hypothesize that the cytokine CCL5 protects AML cells from TKI‐mediated cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Waldeck, Silvia, Rassner, Michael, Keye, Philip, Follo, Marie, Herchenbach, Dieter, Endres, Cornelia, Charlet, Anne, Andrieux, Geoffroy, Salzer, Ulrich, Boerries, Melanie, Duyster, Justus, von Bubnoff, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138400/
https://www.ncbi.nlm.nih.gov/pubmed/31955503
http://dx.doi.org/10.1002/1878-0261.12640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138400/
https://www.ncbi.nlm.nih.gov/pubmed/31955503
http://dx.doi.org/10.1002/1878-0261.12640

Ejemplares similares